What is Alzamend Neuro Operating Cash Flow per Share?
Alzamend Neuro's operating cash flow per share for the
three
months ended in Jan. 2024 was $-0.29.
Alzamend Neuro's operating cash flow per share for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.37.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -51.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Alzamend Neuro's Operating Cash Flow per Share or its related term are showing as below:
ALZN'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -84.6 Med: -68.25 Max: -51.9
Current: -51.9
During the past 5 years, Alzamend Neuro's highest 3-Year average Operating Cash Flow per Share Growth Rate was -51.90% per year. The lowest was -84.60% per year. And the median was -68.25% per year.
Alzamend Neuro Operating Cash Flow per Share Historical Data
The historical data trend for Alzamend Neuro's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro Operating Cash Flow per Share Chart
|
Alzamend Neuro Annual Data
|
|
Trend |
Apr19 |
Apr20 |
Apr21 |
Apr22 |
Apr23 |
| Operating Cash Flow per Share |
|
-0.18 |
-0.39 |
-0.48 |
-1.11 |
-1.37 |
|
Alzamend Neuro Quarterly Data
|
|
Apr19 |
Jan20 |
Apr20 |
Jul20 |
Oct20 |
Jan21 |
Apr21 |
Jul21 |
Oct21 |
Jan22 |
Apr22 |
Jul22 |
Oct22 |
Jan23 |
Apr23 |
Jul23 |
Oct23 |
Jan24 |
| Operating Cash Flow per Share |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
-0.28 |
-0.35 |
-0.50 |
-0.23 |
-0.29 |
Competitive Comparison of Alzamend Neuro's Operating Cash Flow per Share
For the Biotechnology subindustry, Alzamend Neuro's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's Price-to-Operating-Cash-Flow falls into.
Alzamend Neuro Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Alzamend Neuro's Operating Cash Flow per Share for the fiscal year that ended in Apr. 2023 is calculated as
Alzamend Neuro's Operating Cash Flow per Share for the quarter that ended in Apr. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (Alzamend Neuro) Business Description
Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
| Ault Milton C Iii |
10 percent owner |
11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141 |
| David J Katzoff |
officer: Chief Operating Officer |
201 SHIPYARD WAY, NEWPORT BEACH CA 92663 |
| Stephan Jackman |
director, officer: Chief Executive Officer |
C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
| Lynne Fahey Mcgrath |
director |
28145 CEDAR POINT RD., EASTON MD 21601 |
| Mark Gustafson |
director |
10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9 |
| William B. Horne |
director |
C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626 |
| Henry Carl Nisser |
director, officer: Exec VP and General Counsel |
100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017 |
| Kenneth S Cragun |
officer: SVP of Finance |
3775 CHIPPEWA CIRCLE, CORONA CA 92881 |
| Jeffrey Oram |
director |
15 ORCHARD STREET, MENDHAM NJ 07945 |
| Escalona Lien |
officer: Chief Financial Officer |
C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
| Andrew H. Woo |
director |
2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404 |
Alzamend Neuro (Alzamend Neuro) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALZN has been successfully added to your